[Skip to Content]
[Skip to Content Landing]
Article
September 1978

Rational Management of Bronchial Asthma

Author Affiliations

From the Thorndike Memorial Laboratories (Pulmonary Section), Department of Medicine, Boston City Hospital and Boston University School of Medicine.

Arch Intern Med. 1978;138(9):1394-1397. doi:10.1001/archinte.1978.03630340064020
Abstract

Reassessment of rational management of bronchial asthma is timely considering the recent availability of a number of new therapeutic agents such as cromolyn sodium, beclomethasone dipropionate, and sympathomimetics with more specific β2 activity. In addition, there has been a resurgence of interest in the methylxanthine bronchodilators because of their utility. This review will emphasize a general approach to management since recent reviews1-3 have detailed dosages and mechanisms of action of the specific drugs.

Accurate differential diagnosis among the clinically similar but pathophysiologically different bronchial asthma, chronic bronchitis, and pulmonary emphysema is the important basis for selection of appropriate agents for the individual patient. The accepted definition and diagnostic criteria for bronchial asthma are useful.4 However, evidence of the allergic and bronchial pathophysiologic disturbance basic to asthma, such as sputum eosinophilia5 or the hyperreactive airways in response to methylcholine chloride, histamine, or specific antigen, should be documented.

References
1.
Webb-Johnson DC, Andrews JL:  Bronchodilator therapy .  N Engl J Med 297:476-482, 758-764, 1977.Crossref
2.
Flod NE, Franz ML, Galant SP:  Recent advances in bronchial asthma .  Am J Dis Child 130:890-899, 1976.
3.
Van Arsdel PP, Paul GH:  Drug therapy in the management of asthma .  Ann Intern Med 87:68-74, 1977.Crossref
4.
 Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. American Thoracic Society Committee on Diagnostic Standards for Nontuberculous Diseases .  Am Rev Respir Dis 85:762-768, 1962.
5.
Chodosh S:  Sputum cytology in chronic bronchial disease .  Adv Asthma Allergy Pulmon Dis 4( (3) ):8-27, 1977.
6.
Knapp PH, Mathe AA, Vachon L:  Psychosomatic aspects of bronchial asthma , in Weiss EB, Segal MS (eds):  Bronchial Asthma, Mechanisms and Therapeutics . Boston, Little Brown & Co, 1976, pp 1055-1080.
7.
McFadden ER, Kiser R, deGroot WJ:  Acute bronchial asthma: Relations between clinical and physiologic manifestations .  N Engl J Med 288:221-225, 1973.Crossref
8.
Piafsky KM, Ogilvie RI:  Dosage of theophylline in bronchial asthma .  N Engl J Med 292:1218-1222, 1975.Crossref
9.
Smith PR, Heurich AE, Leffler CT, et al:  A comparative study of subcutaneously administered terbutaline and epinephrine in the treatment of acute bronchial asthma .  Chest 71:129-134, 1977.Crossref
10.
Toogood JH, Lefcoe NM, Rose DK, et al:  A double-blind study of disodium cromoglycate for prophylaxis of bronchial asthma .  Am Rev Respir Dis 104:323-330, 1971.
11.
Khurana S, Hyde JS:  Cromolyn sodium, five to six years later .  Ann Allergy 39:94-98, 1977.
12.
Kass I, Nair SV, Patil KD:  Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthmatic patients .  Chest 71:703-707, 1977.Crossref
13.
 A controlled trial of inhaled corticosteroids in patients receiving prednisone tablets for asthma. British Thoracic and Tuberculosis Association .  Br J Dis Chest 70:95-103, 1976.Crossref
×